The low HOXB-AS3-peptide level is correlated with a poor prognosis in CRC patients, and HOXB-AS3-peptide represses colorectal cancer (CRC) growth in vitro and in vivo. This evidence concerns the gene PDS5B and colorectal carcinoma.